Caris Life Sciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $812M+97.0% YoYTTM through 31 Dec 2025
Net Income -$68.1MTTM through 31 Dec 2025
Free Cash Flow $66.9MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 66.0% |
| Operating Margin | 5.6% |
| Net Margin | -8.4% |
Returns
-11.8%ROE
-6.1%ROA
-43.0%ROIC
Balance Sheet Health
Debt / Equity0.66x
Current Ratio7.85x
Net Debt-$421.1Mnet cash position
Cash & Equivalents$797.8M
Quality Metrics
FCF Margin8.2%
Rule of 4035.0
Earnings-Beat Rate75.0%
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Molecular Profiling Services | $766.7M | +120.0% | View detailsExpected to grow approximately 21% to 22% year-over-year in FY 2026 (or 26% to 28% excluding out-of-year over-collections recorded in 2025). |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.